FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893992418> ?p ?o ?g. }

• W2893992418 abstract "Lumacaftor/ivacaftor was approved by the Food and Drug Administration (FDA) as a combination treatment for Cystic Fibrosis (CF) patients who are homozygous for the F508del mutation. The objective of this study was to assess the cost-effectiveness of lumacaftor/ivacaftor combination for the treatment of CF homozygous for F508del CF Transmembrane Conductance Regulator (CFTR) mutation. A Markov-state transition model following a cohort of 12 year-old CF patients homozygous for F508del CFTR mutation in the United States (US) over two, four, six, eight and ten years from a payer’s perspective was developed using TreeAge Pro 2016. Markov states included: mild (percentage of predicted forced expiratory volume in 1 s or FEV1 > 70%), moderate (FEV1 40–70%), severe (FEV1 < 40%) disease, post-transplant, and death. Pulmonary exacerbation and lung transplant were included as transition states. All the input parameters were estimated from the literature. A 1-year cycle length and 3% discount rate were applied. To assess uncertainty in long-term treatment effects, several scenarios were modelled: 100% long-term effectiveness (base-case), defined as improvement in FEV1 in the first year followed by no annual FEV1 decline and a constant reduction in pulmonary exacerbations throughout, 75%, 50%, 25% and 0% (worst case) long-term effectiveness, where treatment effects were intermediate from the second year of treatment until the end of the time horizon. Other scenarios included changing the starting age of the cohort to 6 and 25 years. Primary outcome included incremental cost-effectiveness ratio (ICER) in terms of cost per quality adjusted life year (QALY) gained. One-way and probabilistic sensitivity analyses were performed to determine uncertainty. Under the base-case, Lumacaftor/ivacaftor resulted in higher QALYs (7.29 vs 6.84) but at a very high cost ($1,778,920.88) compared to usual care ($116,155.76) over a 10-year period. The ICER for base-case and worst-case scenarios were $3,655,352 / QALY, and $8,480,265/QALY gained, respectively. In the base-case, lumacaftor/ivacaftor was cost-effective at a threshold of $150,000/QALY-gained when annual drug costs were lower than $4153. The results were not substantially affected by the sensitivity analyses. The intervention produces large QALY gains but at an extremely high cost, resulting in an ICER that would not typically be covered by any insurer. Lumacaftor/ivacaftor’s status as an orphan drug complicates coverage decisions." @default.
• W2893992418 created "2018-10-05" @default.
• W2893992418 creator A5016295149 @default.
• W2893992418 creator A5024849492 @default.
• W2893992418 creator A5049133350 @default.
• W2893992418 creator A5050666513 @default.
• W2893992418 creator A5058551876 @default.
• W2893992418 creator A5086819649 @default.
• W2893992418 date "2018-09-29" @default.
• W2893992418 modified "2023-10-15" @default.
• W2893992418 title "Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States" @default.
• W2893992418 cites W1589654967 @default.
• W2893992418 cites W1859092351 @default.
• W2893992418 cites W1981105254 @default.
• W2893992418 cites W1991980138 @default.
• W2893992418 cites W1993591045 @default.
• W2893992418 cites W2043816730 @default.
• W2893992418 cites W2048091641 @default.
• W2893992418 cites W2058056848 @default.
• W2893992418 cites W2059992865 @default.
• W2893992418 cites W2065306083 @default.
• W2893992418 cites W2097854494 @default.
• W2893992418 cites W2109939030 @default.
• W2893992418 cites W2125270985 @default.
• W2893992418 cites W2131080517 @default.
• W2893992418 cites W2142418276 @default.
• W2893992418 cites W2143843692 @default.
• W2893992418 cites W2171464982 @default.
• W2893992418 cites W2285334580 @default.
• W2893992418 cites W2301131921 @default.
• W2893992418 cites W2441143209 @default.
• W2893992418 cites W2519603001 @default.
• W2893992418 cites W2556613236 @default.
• W2893992418 cites W2568062366 @default.
• W2893992418 cites W2607214168 @default.
• W2893992418 cites W2615423082 @default.
• W2893992418 cites W2741096236 @default.
• W2893992418 cites W2774823352 @default.
• W2893992418 cites W4206217612 @default.
• W2893992418 doi "https://doi.org/10.1186/s13023-018-0914-3" @default.
• W2893992418 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6162947" @default.
• W2893992418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30268148" @default.
• W2893992418 hasPublicationYear "2018" @default.
• W2893992418 type Work @default.
• W2893992418 sameAs 2893992418 @default.
• W2893992418 citedByCount "11" @default.
• W2893992418 countsByYear W28939924182019 @default.
• W2893992418 countsByYear W28939924182020 @default.
• W2893992418 countsByYear W28939924182021 @default.
• W2893992418 countsByYear W28939924182022 @default.
• W2893992418 countsByYear W28939924182023 @default.
• W2893992418 crossrefType "journal-article" @default.
• W2893992418 hasAuthorship W2893992418A5016295149 @default.
• W2893992418 hasAuthorship W2893992418A5024849492 @default.
• W2893992418 hasAuthorship W2893992418A5049133350 @default.
• W2893992418 hasAuthorship W2893992418A5050666513 @default.
• W2893992418 hasAuthorship W2893992418A5058551876 @default.
• W2893992418 hasAuthorship W2893992418A5086819649 @default.
• W2893992418 hasBestOaLocation W28939924181 @default.
• W2893992418 hasConcept C112930515 @default.
• W2893992418 hasConcept C126322002 @default.
• W2893992418 hasConcept C187212893 @default.
• W2893992418 hasConcept C2776502428 @default.
• W2893992418 hasConcept C2776938444 @default.
• W2893992418 hasConcept C2777014857 @default.
• W2893992418 hasConcept C2778428886 @default.
• W2893992418 hasConcept C3019080777 @default.
• W2893992418 hasConcept C64332521 @default.
• W2893992418 hasConcept C71924100 @default.
• W2893992418 hasConcept C72563966 @default.
• W2893992418 hasConceptScore W2893992418C112930515 @default.
• W2893992418 hasConceptScore W2893992418C126322002 @default.
• W2893992418 hasConceptScore W2893992418C187212893 @default.
• W2893992418 hasConceptScore W2893992418C2776502428 @default.
• W2893992418 hasConceptScore W2893992418C2776938444 @default.
• W2893992418 hasConceptScore W2893992418C2777014857 @default.
• W2893992418 hasConceptScore W2893992418C2778428886 @default.
• W2893992418 hasConceptScore W2893992418C3019080777 @default.
• W2893992418 hasConceptScore W2893992418C64332521 @default.
• W2893992418 hasConceptScore W2893992418C71924100 @default.
• W2893992418 hasConceptScore W2893992418C72563966 @default.
• W2893992418 hasIssue "1" @default.
• W2893992418 hasLocation W28939924181 @default.
• W2893992418 hasLocation W28939924182 @default.
• W2893992418 hasLocation W28939924183 @default.
• W2893992418 hasLocation W28939924184 @default.
• W2893992418 hasLocation W28939924185 @default.
• W2893992418 hasOpenAccess W2893992418 @default.
• W2893992418 hasPrimaryLocation W28939924181 @default.
• W2893992418 hasRelatedWork W2059300085 @default.
• W2893992418 hasRelatedWork W2091317180 @default.
• W2893992418 hasRelatedWork W2116885262 @default.
• W2893992418 hasRelatedWork W2128229997 @default.
• W2893992418 hasRelatedWork W2517382167 @default.
• W2893992418 hasRelatedWork W2782678117 @default.
• W2893992418 hasRelatedWork W2888610706 @default.
• W2893992418 hasRelatedWork W3016750854 @default.
• W2893992418 hasRelatedWork W3207166609 @default.
• W2893992418 hasRelatedWork W4300863638 @default.
• W2893992418 hasVolume "13" @default.

• next